Ligon Discovery, Inc., a Harvard spinout that uses proprietary small molecule microarray technology to find drugs against high-value targets, has raised $1m in seed financing.
The funding was led by incTANK Ventures.
The proceeds will be used to complete the company’s initial discovery campaign that will screen over 100 high-value disease protein targets.
In connection with the investment, incTANK Ventures General Partner Christian Bailey joins the board.
Patrick Kleyn PhD, Angela Koehler PhD and Benjamin Ebert MD PhD founded Ligon Discovery with an exclusive license to technology invented at Harvard University and already successfully used to find novel drug compounds at the Broad Institute (founded by MIT and Harvard University) in Cambridge, MA.